School of Medicine
Showing 41-60 of 169 Results
-
Milana V. Dolezal, MD, MSci
Clinical Associate Professor, Medicine - Oncology
BioDr. Dolezal is a board-certified hematologist-oncologist with Stanford Medicine Cancer Center in Emeryville and a clinical associate professor in the Stanford School of Medicine, Division of Oncology.
She strives to work with patients to develop care plans that are comprehensive and personalized achieve the best possible outcomes and quality of life.
Dr. Dolezal also has extensive experience in research and drug development. She previously held positions as a clinical scientist, assistant medical director, and associate medical director in the BioOncology Therapeutics unit of the biotechnology company Genentech.
She has conducted clinical research into fertility preservation in patients with breast cancer, advanced treatments for triple-negative breast cancer, and patients’ adherence to anti-cancer therapy. She has co-authored articles on her research findings that appeared in the Journal of Clinical Oncology, Cancer, and other peer-reviewed publications.
She also co-authored the chapter “Progression from Hormone-Dependent to Hormone-Independent Breast Cancer” in the textbook Hormones, Genes and Cancer published by Oxford University Press.
Dr. Dolezal has made presentations to her peers at meetings of the American Association for Cancer Research, American Society of Clinical Oncology, and European Cancer Organisation. -
George Duran
Cancer Biologist and Laboratory Manager, Medicine - Med/Oncology
Current Role at StanfordCancer biologist specializing in the development of novel chemotherapeutic agents and in mechanisms of drug resistance. Current research ranges from molecular studies to further understand the heterogeneity of T-cell lymphomas, to translational studies of molecular determinants of therapeutic response, and clinical trials that use the body’s immune system to fight cancer cells.
Original research contributions have resulted in the authorship of over eighty publications. -
Timothy Ellis-Caleo, MD
Clinical Assistant Professor, Medicine - Oncology
BioDr. Timothy Ellis-Caleo is a board-certified, fellowship-trained medical oncologist with Stanford Health Care. He is also a clinical assistant professor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Ellis-Caleo specializes in caring for people with thoracic and gastrointestinal cancers. His clinical interests include immunotherapy and precision oncology, with a focus on bringing the latest advances in cancer treatment to patients. He works closely with each patient to develop personalized treatment plans that reflect their goals, values, and individual needs while incorporating evidence-based therapies and access to innovative clinical trials when appropriate.
As a physician-researcher, Dr. Ellis-Caleo focuses on improving treatments for patients with solid tumors through translational research and clinical investigation. His research has explored the tumor microenvironment and its role in predicting response to immunotherapy, molecular biomarkers for lung cancer, and the use of artificial intelligence to improve cancer care and surveillance.
Dr. Ellis-Caleo has authored numerous peer-reviewed publications in leading medical journals, including Nature Cancer, Nature Communications, NPJ Digital Medicine, and Journal of Clinical Oncology (JCO) Precision Oncology. He has presented his research at national and international meetings, including the American Society of Clinical Oncology Annual Meeting and the World Conference on Lung Cancer.
Dr. Ellis-Caleo is a member of Alpha Omega Alpha Honor Medical Society and Sigma Xi, The Scientific Research Honor Society. -
Alice C. Fan
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsDr. Fan is a physician scientist who studies how turning off oncogenes (cancer genes) can cause tumor regression in preclinical and clinical translational studies. Based on her findings, she has initiated clinical trials studying how targeted therapies affect cancer signals in kidney cancer and low grade lymphoma. In the laboratory, she uses new nanotechnology strategies for tumor diagnosis and treatment to define biomarkers for personalized therapy.
-
Dean W. Felsher
Professor of Medicine (Oncology) and of Pathology
Current Research and Scholarly InterestsMy laboratory studies the molecular basis of cancer with a focus on understanding when cancer can be reversed through targeted oncogene inactivation.
-
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine, Emeritus
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
James Ford
Professor of Medicine (Oncology) of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNAdamage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Kristen N Ganjoo
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsGiant cell tumor of the bone
Gastrointestinal stromal tumors
Soft tissue sarcoma
Osteosarcoma -
Joshua Gruber
Associate Professor of Medicine (Oncolocy)
BioDr. Joshua Gruber is an Associate Professor of Medicine in the division of Oncology at Stanford University Medical Center. He received his Bachelors of Arts, Summa Cum Laude, in biochemistry and physics from the University of Pennsylvania in 2001. He then graduated from the Medical Scientist Training Program at the University of Pennsylvania where he performed doctoral studies in cancer biology and biochemistry. He completed internship and residency in Internal Medicine at Stanford, then was a Clinical Fellowship in Medical Oncology and also a Postdoctoral Fellow in Genetics at Stanford, working in the laboratory of Michael Snyder on integrative genomics of hereditary breast cancer. He is currently has a clinical focus on treating patients with metastatic breast cancer and triple-negative breast cancer and conducts clinical trials on novel therapeutics for these diseases. His laboratory research interests include the molecular biology of breast cancer initiation, the intersection of tumor immunology with cancer growth pathways and the development of molecular tools to interrogate neoplastic tissues.
-
Mengni Guo
Clinical Assistant Professor, Medicine - Oncology
BioDr. Mengni Guo is a medical oncologist in the Division of Oncology at Stanford University School of Medicine and a member of the Stanford Breast Cancer Program. She specializes in the care of patients with breast cancer, from active treatment through long-term survivorship. Dr. Guo emphasizes an individualized, team-based approach, working closely with patients and multidisciplinary specialists to develop treatment plans that reflect each patient’s clinical needs, personal values, and long-term quality of life.
Dr. Guo’s research focuses on breast cancer survivorship, particularly metabolic health during and after cancer treatment and the prevention and management of long-term treatment effects. She also uses large real-world datasets to study breast cancer treatment patterns and outcomes and to identify strategies to improve long-term health after cancer therapy. Her research has been presented at national meetings, including the American Society of Clinical Oncology (ASCO) Annual Meeting. -
Neel K. Gupta
Clinical Associate Professor, Medicine - Oncology
Current Research and Scholarly InterestsI have specific interest in the pathobiology and management of individuals with AIDS-related and primary central nervous system lymphomas.